Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for allegedly engaging in a fraudulent stock promotion scheme that misled investors and artificially inflated its stock price [1][2]. Group 1: Allegations and Investigations - The complaint alleges that Charming Medical failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - Public reports indicate that Charming's stock price surged from an initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news justifying such a spike [3]. Group 2: Trading Suspension - On November 12, 2025, the SEC halted trading of Charming's stock due to the lack of required information from the Company to lift the suspension [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Charming Medical, with options to serve as lead plaintiff or remain an absent class member [4].